Terms: = Leukemia AND DNMT3A, Q9Y6K1, 1788, ENSG00000119772, DNMT3A2, M_HsaIIIA
928 results:
1. Measurable residual disease monitoring by ddPCR in the early posttransplant period complements the traditional MFC method to predict relapse after HSCT in AML/MDS: a multicenter retrospective study.
Chen W; Huang J; Zhao Y; Huang L; Yuan Z; Gu M; Xu X; Shi J; Luo Y; Yu J; Lai X; Liu L; Fu H; Bao C; Huang X; Zheng Z; Huang H; Hu X; Zhao Y
J Transl Med; 2024 Apr; 22(1):410. PubMed ID: 38689269
[TBL] [Abstract] [Full Text] [Related]
2. Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients.
Borsi E; Vigliotta I; Poletti A; Mazzocchetti G; Solli V; Zazzeroni L; Martello M; Armuzzi S; Taurisano B; Kanapari A; Pistis I; Zamagni E; Pantani L; Rocchi S; Mancuso K; Tacchetti P; Rizzello I; Rizzi S; Dan E; Sinigaglia B; Cavo M; Terragna C
Cells; 2024 Apr; 13(8):. PubMed ID: 38667272
[TBL] [Abstract] [Full Text] [Related]
3. A novel t(X;21)(p11.4;q22.12) translocation adds to the role of BCOR and RUNX1 in myelodysplastic syndromes and acute myeloid leukemias.
Mavridou E; Lema Fernandez AG; Nardelli C; Pierini V; Quintini M; Arniani S; Di Giacomo D; Crescenzi B; Matteucci C; Sambani C; Mecucci C
Genes Chromosomes Cancer; 2024 Apr; 63(4):e23235. PubMed ID: 38656651
[TBL] [Abstract] [Full Text] [Related]
4. A Case of Chronic Eosinophilic leukemia with CSF3R-Mutant Clone and Transformed to Secondary Acute Myeloid leukemia.
Wu Y; Yang X
Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623671
[TBL] [Abstract] [Full Text] [Related]
5. Structure-guided functional suppression of AML-associated dnmt3a hotspot mutations.
Lu J; Guo Y; Yin J; Chen J; Wang Y; Wang GG; Song J
Nat Commun; 2024 Apr; 15(1):3111. PubMed ID: 38600075
[TBL] [Abstract] [Full Text] [Related]
6. Study of the effect of sFRP1 protein on molecules involved in the regulation of DNA methylation in CML cell line.
Demirkiran N; Aydin B; Pehlivan M; Yuce Z; Sercan HO
Med Oncol; 2024 Apr; 41(5):109. PubMed ID: 38592567
[TBL] [Abstract] [Full Text] [Related]
7. Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML.
Risueño A; See WL; Bluemmert I; de Botton S; DiNardo CD; Fathi AT; Schuh AC; Montesinos P; Vyas P; Prebet T; Gandhi A; Hasan M
Leuk Res; 2024 May; 140():107497. PubMed ID: 38564986
[TBL] [Abstract] [Full Text] [Related]
8. Sweet syndrome induced by FLT3 inhibitors: case report and literature review.
Yang L; Zhang R; Ma H
Hematology; 2024 Dec; 29(1):2337230. PubMed ID: 38563968
[TBL] [Abstract] [Full Text] [Related]
9. Natural history of clonal haematopoiesis seen in real-world haematology settings.
Patel SA; Gerber WK; Zheng R; Khanna S; Hutchinson L; Abel GA; Cerny J; DaSilva BA; Zhang TY; Ramanathan M; Khedr S; Selove W; Woda B; Miron PM; Higgins AW; Gerber JM
Br J Haematol; 2024 May; 204(5):1844-1855. PubMed ID: 38522849
[TBL] [Abstract] [Full Text] [Related]
10. Comparison of clinical outcomes of several risk stratification tools in newly diagnosed AML patients: A real-world evidence in our current therapeutic era.
Iat A; Loschi M; Benachour S; Calleja A; Chiche E; Sudaka I; Aquaronne D; Ferrero C; Fenwarth L; Marceau A; Fournier E; Dadone-Montaudie B; Cluzeau T
Cancer Med; 2024 Mar; 13(6):e7103. PubMed ID: 38506267
[TBL] [Abstract] [Full Text] [Related]
11. Cancer patients with clonal hematopoiesis die from primary malignancy or comorbidities despite higher rates of transformation to myeloid neoplasms.
Chien KS; Ong F; Kim K; Li Z; Kanagal-Shamanna R; DiNardo CD; Takahashi K; Montalban-Bravo G; Hammond D; Sasaki K; Pierce SA; Kantarjian HM; Garcia-Manero G
Cancer Med; 2024 Mar; 13(5):e7093. PubMed ID: 38497538
[TBL] [Abstract] [Full Text] [Related]
12. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management.
Patnaik MM; Tefferi A
Am J Hematol; 2024 Jun; 99(6):1142-1165. PubMed ID: 38450850
[TBL] [Abstract] [Full Text] [Related]
13. Liquid biopsy-based circulating tumour (ct)DNA analysis of a spectrum of myeloid and lymphoid malignancies yields clinically actionable results.
Mata DA; Lee JK; Shanmugam V; Marcus CB; Schrock AB; Williams EA; Ritterhouse LL; Hickman RA; Janovitz T; Patel NR; Kroger BR; Ross JS; Mirza KM; Oxnard GR; Vergilio JA; Elvin JA; Benhamida JK; Decker B; Xu ML
Histopathology; 2024 Jun; 84(7):1224-1237. PubMed ID: 38422618
[TBL] [Abstract] [Full Text] [Related]
14. The crossroads of cancer therapies and clonal hematopoiesis.
Singh A; Balasubramanian S
Semin Hematol; 2024 Feb; 61(1):16-21. PubMed ID: 38403501
[TBL] [Abstract] [Full Text] [Related]
15. [The Correlation of Gene Mutation and Clinical Characteristics in Patients with Myelodysplastic Syndrome and Prognostic Analysis].
Zhang WW; Zhang YL; Ren CC; Wu TK; Liu B
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):176-183. PubMed ID: 38387918
[TBL] [Abstract] [Full Text] [Related]
16. Mechanisms of action and resistance in histone methylation-targeted therapy.
Yamagishi M; Kuze Y; Kobayashi S; Nakashima M; Morishima S; Kawamata T; Makiyama J; Suzuki K; Seki M; Abe K; Imamura K; Watanabe E; Tsuchiya K; Yasumatsu I; Takayama G; Hizukuri Y; Ito K; Taira Y; Nannya Y; Tojo A; Watanabe T; Tsutsumi S; Suzuki Y; Uchimaru K
Nature; 2024 Mar; 627(8002):221-228. PubMed ID: 38383791
[TBL] [Abstract] [Full Text] [Related]
17. Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt-related transcription factor 1 mutation: A single-center retrospective analysis.
Wang LY; Li Y; Jiang Q; Jiang H; Wang Y; Xu LP; Zhang XH; Liu KY; Tang FF
Hematol Oncol; 2024 Mar; 42(2):e3256. PubMed ID: 38367260
[TBL] [Abstract] [Full Text] [Related]
18. CALCRL knockdown suppresses cancer stemness and chemoresistance in acute myeloid leukemia with FLT3-ITD and DNM3TA-R882 double mutations.
Tang S; Zhu H; Sheng L; Mu Q; Wang Y; Xu K; Zhou M; Xu Z; Wu A; Ouyang G
Drug Dev Res; 2024 Feb; 85(1):e22137. PubMed ID: 38349260
[TBL] [Abstract] [Full Text] [Related]
19. Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax-based therapy.
Weng G; Huang J; An N; Zhang Y; Yu G; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; He X; Jin H; Liu Q; Du X
Cancer Med; 2024 Jan; 13(2):e6885. PubMed ID: 38334500
[TBL] [Abstract] [Full Text] [Related]
20. Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents.
Johnson IM; Karrar O; Rana M; Iftikhar M; Chen S; McCullough K; Saliba AN; Al-Kali A; Alkhateeb H; Begna K; Litzow M; Hogan WJ; Shah M; Patnaik MM; Pardanani A; Hermann J; Tefferi A; Gangat N
Br J Haematol; 2024 Apr; 204(4):1232-1237. PubMed ID: 38311378
[TBL] [Abstract] [Full Text] [Related]
[Next]
